{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:07:25Z","timestamp":1782936445010,"version":"3.54.5"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006316","name":"Alliance for Clinical Trials in Oncology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 CA273043"],"award-info":[{"award-number":["K08 CA273043"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Demographic enrollment disparities in adult acute leukemia clinical trials limit generalizability and diminish opportunities for minoritized populations to benefit from novel therapies. The distinct natural history and clinical research landscape of acute leukemia, the latter of which is centralized at the National Cancer Institute-designated Comprehensive Cancer Centers (CCCs), pose challenges to eliminating this disparity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We performed an analysis of 2 qualitative focus group and interview-based studies to characterize barriers and facilitators to representative acute leukemia clinical trial participation. Participants were patients with acute leukemia belonging to under-enrolled demographic groups (female, older adults, Hispanic ethnicity, or non-White race) and clinicians who treat and enroll them in clinical trials at CCCs in Massachusetts and Ohio.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eight focus groups and 7 individual interviews were performed with 61 participants (34 patients and 27 clinicians). Barriers idiosyncratic to acute leukemia included inpatient and resource-intensive outpatient care, limited time between diagnosis and treatment initiation, low disease prevalence leading to trial centralization, and barriers related to hematopoietic stem cell transplantation. Barriers common across cancer types included restrictive eligibility criteria, complex study logistics, and cost. Potential solutions included local hospital and CCC partnerships and navigation to enhance timely referral and co-management during participation, multi-modal trial education and peer support in the peri-diagnostic period, minimizing unnecessary eligibility criteria, and travel and financial assistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients and clinicians identified actionable steps to improve trial participation that address the unique challenges for adults with acute leukemia. A multi-pronged and disease-specific approach is needed to achieve representative acute leukemia clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf241","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T21:43:16Z","timestamp":1755034996000},"source":"Crossref","is-referenced-by-count":4,"title":["Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9612-3643","authenticated-orcid":false,"given":"Andrew","family":"Hantel","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]},{"name":"HMS Center for Bioethics , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C","family":"Blackstone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]},{"name":"HMS Center for Bioethics , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C","family":"Revette","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice S","family":"Mims","sequence":"additional","affiliation":[{"name":"The Ohio State University , Columbus, OH 43210,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S","family":"Lathan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A","family":"Abel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA 02115,","place":["United States"]},{"name":"HMS Center for Bioethics , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"2025091815424615900_oyaf241-B1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/107327481602300404","article-title":"Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer","volume":"23","author":"Hamel","year":"2016","journal-title":"Cancer Control"},{"key":"2025091815424615900_oyaf241-B2","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood"},{"key":"2025091815424615900_oyaf241-B3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"The role of clinical trial participation in cancer research: barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025091815424615900_oyaf241-B4","author":"N"},{"key":"2025091815424615900_oyaf241-B5"},{"key":"2025091815424615900_oyaf241-B6","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1182\/bloodadvances.2021005148","article-title":"Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials","volume":"5","author":"Hantel","year":"2021","journal-title":"Blood Adv"},{"key":"2025091815424615900_oyaf241-B7","doi-asserted-by":"publisher","first-page":"e191870","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025091815424615900_oyaf241-B8","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1200\/JCO.22.00307","article-title":"Inequities in alliance acute leukemia clinical trial and biobank participation: defining targets for intervention","volume":"40","author":"Hantel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025091815424615900_oyaf241-B9","doi-asserted-by":"publisher","first-page":"100670","DOI":"10.1016\/j.blre.2020.100670","article-title":"Older adults in hematologic malignancy trials: representation, barriers to participation and strategies for addressing underrepresentation","volume":"43","author":"Kanapuru","year":"2020","journal-title":"Blood Rev"},{"key":"2025091815424615900_oyaf241-B10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/leu.2015.188","article-title":"Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in The Netherlands, 1989-2012","volume":"30","author":"Dinmohamed","year":"2016","journal-title":"Leukemia"},{"key":"2025091815424615900_oyaf241-B11","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/bjh.20044","article-title":"Are we ignoring sex differences in haematological malignancies? A call for improved reporting","volume":"206","author":"Paltiel","year":"2025","journal-title":"Br J Haematol"},{"key":"2025091815424615900_oyaf241-B12","first-page":"216","article-title":"Strategies for overcoming disparities for patients with hematologic malignancies and for improving enrollment on clinical trials","volume":"34","author":"Williams","year":"2020","journal-title":"Oncology (Williston Park)"},{"key":"2025091815424615900_oyaf241-B13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/EDBK_243729","article-title":"Overcoming barriers to clinical trial enrollment","volume":"39","author":"Nipp","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025091815424615900_oyaf241-B14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025091815424615900_oyaf241-B15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/jnci\/djaa155","article-title":"\u201cWhen offered to participate\u201d: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials","volume":"113","author":"Unger","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025091815424615900_oyaf241-B16","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.2105\/AJPH.2006.102525","article-title":"Approaching health disparities from a population perspective: the National Institutes of Health centers for population health and health disparities","volume":"98","author":"Warnecke","year":"2008","journal-title":"Am J Public Health"},{"key":"2025091815424615900_oyaf241-B17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/1055-9965.EPI-16-0722","article-title":"Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: impact of care at specialized cancer centers on survival outcome","volume":"26","author":"Wolfson","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025091815424615900_oyaf241-B18","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/cncr.31296","article-title":"Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California","volume":"124","author":"Ho","year":"2018","journal-title":"Cancer"},{"key":"2025091815424615900_oyaf241-B19","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1002\/cncr.29576","article-title":"Impact of care at comprehensive cancer centers on outcome: results from a population-based study","volume":"121","author":"Wolfson","year":"2015","journal-title":"Cancer"},{"key":"2025091815424615900_oyaf241-B20","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/jnci\/djae067","article-title":"Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia","volume":"116","author":"Hantel","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2025091815424615900_oyaf241-B21","author":"NIMHD Research Framework"},{"key":"2025091815424615900_oyaf241-B22","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","article-title":"Sample size in qualitative interview studies","volume":"26","author":"Malterud","year":"2016","journal-title":"Qual Health Res"},{"key":"2025091815424615900_oyaf241-B23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1049732316665344","article-title":"Code saturation versus meaning saturation","volume":"27","author":"Hennink","year":"2017","journal-title":"Qual Health Res"},{"key":"2025091815424615900_oyaf241-B24","volume-title":"Successful Qualitative Research\u202f: A Practical Guide for Beginners","author":"Braun","year":"2013"},{"key":"2025091815424615900_oyaf241-B25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4135\/9781849209878","volume-title":"Reworking Qualitative Data","author":"Heaton","year":"2004"},{"key":"2025091815424615900_oyaf241-B26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/jamaoncol.2024.5786","article-title":"Shared local oncology care after allogeneic hematopoietic cell transplantation: a randomized controlled trial","volume":"11","author":"Abel","year":"2025","journal-title":"JAMA Oncol"},{"key":"2025091815424615900_oyaf241-B27","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/bmt.2016.164","article-title":"A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions","volume":"51","author":"Applebaum","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2025091815424615900_oyaf241-B28","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s41409-024-02327-x","article-title":"Disparities in access to hematopoietic cell transplant persist at a transplant center","volume":"59","author":"Shoag","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2025091815424615900_oyaf241-B29"},{"key":"2025091815424615900_oyaf241-B30","year":"2024"},{"key":"2025091815424615900_oyaf241-B31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1634\/theoncologist.2019-0146","article-title":"Addressing the financial burden of cancer clinical trial participation: longitudinal effects of an equity intervention","volume":"24","author":"Nipp","year":"2019","journal-title":"Oncologist"},{"key":"2025091815424615900_oyaf241-B32","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMp1103502","article-title":"Pragmatic trials\u2014guides to better patient care?","volume":"364","author":"Ware","year":"2011","journal-title":"N Engl J Med"},{"key":"2025091815424615900_oyaf241-B33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jgo.2016.02.005","article-title":"Pragmatic study designs for older adults with cancer: report from the U13 conference","volume":"7","author":"Nipp","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"2025091815424615900_oyaf241-B34","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1002\/cncr.34894","article-title":"Systematic review and meta-analysis: prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia","volume":"129","author":"Franco","year":"2023","journal-title":"Cancer"},{"key":"2025091815424615900_oyaf241-B35","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat Med"},{"key":"2025091815424615900_oyaf241-B36","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3324\/haematol.2024.285225","article-title":"Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens","volume":"109","author":"Baden","year":"2024","journal-title":"Haematologica"},{"key":"2025091815424615900_oyaf241-B37","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1037\/hea0000097","article-title":"Reducing patients\u2019 anxiety and uncertainty, and improving recall in bad news consultations","volume":"33","author":"van Osch","year":"2014","journal-title":"Health Psychol"},{"key":"2025091815424615900_oyaf241-B38","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1200\/OP.20.00646","article-title":"Anxiety shapes expectations of therapeutic benefit in phase I trials for patients with advanced cancer and spousal caregivers","volume":"17","author":"Hlubocky","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2025091815424615900_oyaf241-B39","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10903-015-0198-9","article-title":"A review of barriers to minorities\u2019 participation in cancer clinical trials: implications for future cancer research","volume":"18","author":"Salman","year":"2016","journal-title":"J Immigr Minor Health"},{"key":"2025091815424615900_oyaf241-B40","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025091815424615900_oyaf241-B41","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1634\/theoncologist.2017-0628","article-title":"At what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials","volume":"23","author":"Borno","year":"2018","journal-title":"Oncologist"},{"key":"2025091815424615900_oyaf241-B42","doi-asserted-by":"publisher","first-page":"JCO1801132","DOI":"10.1200\/JCO.18.01132","article-title":"Addressing financial barriers to patient participation in clinical trials: ASCO policy statement","author":"Winkfield","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025091815424615900_oyaf241-B43","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3324\/haematol.2023.283723","article-title":"Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia","volume":"109","author":"Hantel","year":"2024","journal-title":"Haematologica"},{"key":"2025091815424615900_oyaf241-B44","author":"Food and Drug Administration Oncology Center of Excellence","year":"2020"},{"key":"2025091815424615900_oyaf241-B45","author":"Food and Drug Administration Oncology Center of Excellence","year":"2020"},{"key":"2025091815424615900_oyaf241-B46","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025091815424615900_oyaf241-B47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10549-020-05873-2","article-title":"Increasing accrual of minority patients in breast cancer clinical trials","volume":"184","author":"Trant","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2025091815424615900_oyaf241-B48","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamaoncol.2023.2800","article-title":"Medicaid expansion of the patient protection and affordable care act and participation of patients with Medicaid in cancer clinical trials","volume":"9","author":"Unger","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025091815424615900_oyaf241-B49","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1200\/JCO.23.01149","article-title":"Association between state Medicaid policies and accrual of Black or Hispanic patients to cancer clinical trials","volume":"42","author":"Schpero","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025091815424615900_oyaf241-B50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1001\/jamaoncol.2021.6011","article-title":"Diversity trends by sex and underrepresented in medicine status among US radiation and medical oncology faculty over 5 decades","volume":"8","author":"Kamran","year":"2022","journal-title":"JAMA Oncology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf241\/63992281\/oyaf241.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf241\/63992281\/oyaf241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf241\/63992281\/oyaf241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:42:54Z","timestamp":1758224574000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf241\/8228585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf241","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,8]]},"article-number":"oyaf241"}}